C-MER Medical Holdings Limited (HKG:3309)
Hong Kong · Delayed Price · Currency is HKD 1.840
-0.020 (-1.08%)
Aug 12, 2025, 3:59 PM HKT
Paramount Global Revenue
In the year 2024, C-MER Medical Holdings had annual revenue of 1.91B HKD, down -0.56%. C-MER Medical Holdings had revenue of 990.66M in the half year ending December 31, 2024, with 16.50% growth.
Revenue
1.91B
Revenue Growth
-0.56%
P/S Ratio
1.20
Revenue / Employee
937.37K
Employees
2,041
Market Cap
2.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.91B | -10.80M | -0.56% |
| Dec 31, 2023 | 1.92B | 192.06M | 11.09% |
| Dec 31, 2022 | 1.73B | 619.33M | 55.67% |
| Dec 31, 2021 | 1.11B | 413.03M | 59.04% |
| Dec 31, 2020 | 699.55M | 123.34M | 21.40% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 35.81B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |